Quantcast

Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast

April 9, 2009

SUNNYVALE, Calif., April 9 /PRNewswire-FirstCall/ — Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its fiscal first quarter ended March 31, 2009, on Thursday, April 23, 2009, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 23, 2009, to discuss the results. To access the live webcast, please visit Cepheid’s website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 700-6067 (domestic) or (617) 213-8834 (international), and entering participant code 21782083. A replay will be available for seven days beginning at 4 p.m. Pacific Time. Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with participant code 78028998.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

    CONTACTS:
    For Media Inquiries:                 For Investor Inquiries:
    Jared Tipton                         Jacquie Ross
    Cepheid Corporate                    Cepheid Investor
    Communications                       Relations
    Tel: (408) 400 8377                  Tel: (408) 400 8329
    jared.tipton@cepheid.com             investor.relations@cepheid.com

SOURCE Cepheid


Source: newswire



comments powered by Disqus